Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 10/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 10/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16766909 | 1.00 | HCRTR1 (0.47) | HCRTR1HCRTR2CYP3A4CHRM1MAPT | |
| SCHEMBL17580154 | 0.85 | HCRTR1 (0.46) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL17580156 | 0.85 | HCRTR1 (0.46) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL16767567 | 0.82 | HCRTR1 (0.46) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL16767565 | 0.82 | HCRTR1 (0.46) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL14940433 | 0.81 | HCRTR1 (0.51) | HCRTR1HCRTR2CYP3A4CHRM1 | |
| SCHEMBL14940431 | 0.81 | HCRTR1 (0.51) | HCRTR1HCRTR2CYP3A4CHRM1 | |
| SCHEMBL27965586 | 0.80 | HCRTR1 (0.48) | HCRTR1HCRTR2CYP3A4CHRM1MEN1 | |
| SCHEMBL27965585 | 0.80 | HCRTR1 (0.48) | HCRTR1HCRTR2CYP3A4CHRM1MEN1 | |
| SCHEMBL16767251 | 0.73 | HCRTR1 (0.50) | HCRTR1HCRTR2CYP3A4MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776430-B1 | 2- (1,2,3-TRIAZOL-2-YL) BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL) PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-16 | — | — | EP | disclosed |
| US-9150566-B2 | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-10-06 | — | — | US | disclosed |
| US-20150158855-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158855-A1 | 2-(1,2,3-TRIAZOL-2-YL)BENZAMIDE AND 3-(1,2,3-TRIAZOL-2-YL)PICOLINAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885CYP3A4 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.